• Original article (Clinical research) •

### Study on the value of serum PGE2 in patients with cirrhosis in decompensation stage for predicting infections

HUANG Xiao-ping, WANG Yan, SUN Wei, HUANG Yan, CHEN Li, GAN Jian-he

1. Department of Infectious Disease, The First Affiliated Hospital of Suzhou University, Suzhou 215006, China
• Online:2016-07-28 Published:2016-08-31
• Supported by:

Major Science and Technology Program of Ministry of Science and Technology in the National “12th 5-year Plan” of China, 2012X10002004-008

Abstract:

Objective To measure the serum PGE2 level in patients with cirrhosis in decompensation stage and explore the value for predicting the risk of infections. Methods Serum PGE2 levels in 167 patients with cirrhosis in decompensation stage who were assigned to the non-infection group (n=133) and the infection group (n=34) and 65 patients with cirrhosis in compensation stage (the control group) were measured with ELISA. The value for predicting the risk of infections in patients with cirrhosis was analyzed. Results Significantly higher PGE2 levels were found in the non-infection group and the infection group than that in the control group (P=0.000 0). The PGE2 levels were significantly higher in the infection group than that in the non-infection group (P=0.000 0). The area under the receiver operating characteristic curve for predicting the risk of infections was 0.82 (95%CI: 0.76-0.90). The sensitivity and specificity of PGE2 of 2 637 pg/mL for predicting the infections in patients with cirrhosis in decompensation stage were 0.824 and 0.777， respectively. Conclusion PGE2 can reflect the state of immune function in patients with cirrhosis in decompensation stage to a certain extent. Increased PGE2 level suggests a higher risk of infections.